Bispecific Antibodies Latch Onto Advances – Module 1

Program Overview

Navigating the Frontier of Hematologic Malignancy Therapies (1 of 5 Modules)

This activity provides an overview of data for new and emerging T-cell directed bispecific antibodies in the management of hematologic malignancies, with a focus on multiple myeloma.

Credit Expired

Target Audience

Hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze available data on bispecific antibodies for the treatment of multiple myeloma

Activity Faculty

Saad Z. Usmani, MD, MBA, FACP

Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Featured RMEI CE Activities – Earn CE Credit(s)

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

1.25 CE Credit(s)

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

1.0 CE Credit(s)

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

0.75 CE Credit(s)

Privacy | Terms of Use